profit from every $100 of sales.
$0$100
Serina Therapeutics
$1.39-1.42% today
-64.5% in 1 year
1-year low $1.281-year high $4.26
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2023.
0%20% a year
You pay $7.01 for every $1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Serina Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $500,000 in 2022 to $0 in 2025, with -$19.2 million of profit last year.
SalesProfit
Serina Therapeutics vs. similar companies
Serina Therapeutics grows the fastest of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Serina Therapeutics | 7.0× · Cheap | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Serina Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 1 | 3 | 0 | 0 | |
| – | – | – | – | |
| -2 | -3 | -17 | -24 | |
| -3 | 6 | -10 | -19 | |
| -3 | 5 | -11 | -19 | |
| -1.23 | 0.63 | -1.51 | -1.91 | |
| – | – | – | – | |
| -454.1% | -104.3% | – | – | |
| -536.4% | 175.6% | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 1 | 9 | 7 | 7 |
| Cash | 1 | 8 | 4 | 3 |
| Total debt | 2 | 3 | 0 | 3 |
| Total liabilities | 39 | 41 | 6 | 7 |
| -38 | -32 | 1 | -0 | |
| 8 | 8 | 7 | 10 | |
| – | – | -928.3% | -483.0% | |
| 7.1% | -16.3% | -1,738.1% | 51,843.2% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -2 | -2 | -17 | -18 | |
| 0 | 1 | 0 | 0 | |
| -2 | -3 | -17 | -18 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 0 | 0 | 3 | 4 |
Valuation
- 7.0×
- –
- –
- -482.0×
- 12.3×
- –
- 5.5×
- -8.1%
- 14.3%
- 0.0%
Profitability
- 43.8%
- -104.3%
- 175.6%
- -16,939.2%
- -709.0%
- -2,721.3%
- -1,468.2%
- -276.0%
- -709.0%
- 10,106.2%
Growth
- +500.0%
- –
- −4.6%
- –
- +75.4%
Financial health
- -0.0×
- -84.92
- 45.2%
- -112.8×
- 1.71
- 1.71
- 0.02
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 3%of 894
Top 5%of 632
Bottom 11%of 991
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 14, 2026 | -0.58 | -0.44 | −31.8% |
| Mar 25, 2026 | -0.31 | -0.50 | +38.0% |
| Nov 13, 2025 | -0.45 | -0.47 | +4.3% |
| Aug 11, 2025 | -0.66 | -0.36 | −83.3% |
| May 8, 2025 | -0.49 | -0.62 | +21.0% |
| Mar 24, 2025 | -0.27 | 0.42 | −164.3% |
| Nov 12, 2024 | 0.13 | – | – |
| Aug 9, 2024 | 0.51 | – | – |
News
E-L Financial Corporation Limited PFD 1ST SER 3 declares CAD 0.3438 dividendSeeking Alpha · Nov 11, 2026E-L Financial Corporation Limited PFD 1ST SER 1 declares CAD 0.3312 dividendSeeking Alpha · Nov 11, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/6Passes 2 of 6. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
51No pass
Benjamin Graham
64Pass
Philip Fisher
54No pass
Peter Lynch
–Not enough data
Joel Greenblatt
99Pass
Charlie Munger
57No pass
Terry Smith
54No pass
Questions about Serina Therapeutics
Is Serina Therapeutics a good stock to buy?
A strong, very profitable business, and the price looks low. 2 of the 6 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Serina Therapeutics AI analysis
What does Serina Therapeutics do?
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. It is in Biotechnology.
Does Serina Therapeutics pay a dividend?
No. Serina Therapeutics does not pay a dividend at the moment.
Is Serina Therapeutics stock halal?
Yes. Serina Therapeutics passes our halal screen: its business is permitted and its debt is 9% of its market value, under the 30% limit. How we check
How has Serina Therapeutics stock done over the past year?
Down 64.5% over the past twelve months, to $1.39. It traded between $1.28 and $4.26 and is 67.4% below its high.
Who are Serina Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Serina Therapeutics's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.